Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: drkazmd65, The_Q
Search This Board: 
Last Post: 5/21/2022 2:49:41 PM - Followers: 381 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4





Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.CANCER - MULTIKINE

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

    Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1


https://frugalnorwegian.com/cvm  Insight into CVM P3 Trial Results

https://www.cvmresearch.com  Insight into CVM P3 Trial Results & FDA Chances of Approval

CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results 05/16/2022 04:50:00 AM
CVM News: Additional Proxy Soliciting Materials (definitive) (defa14a) 04/29/2022 12:14:26 PM
CVM News: Annual Report to Security Holders (ars) 04/29/2022 12:13:54 PM
CVM News: CEL-SCI Announces Acceptance of Abstracts to ASCO 2022 04/22/2022 05:21:00 AM
CVM News: Amended Statement of Ownership (sc 13g/a) 04/11/2022 09:55:57 AM
PostSubject
#40118  Sticky Note CEL-SCI: Pivotal Clinical Trial Results Point To Upside conix 07/14/21 05:52:06 PM
#41520   Missing one, W_W 05/21/22 02:49:41 PM
#41519   "daily short volume"s meaningless intra-day order processing volume. Homebrew 05/21/22 02:56:38 AM
#41518   72.65% daily short volume but PPS didn't go Phoenix2020 05/21/22 02:53:33 AM
#41517   From Zach's SCR: DocKB 05/20/22 01:13:50 PM
#41516   47.40% daily short volume but PPS up 2.29%! Phoenix2020 05/20/22 03:45:42 AM
#41515   I've been buying small lots of shares steadily drkazmd65 05/18/22 08:46:26 AM
#41514   Actually, according to the ASCO 2022 website, the Kpauliukonis 05/18/22 08:37:18 AM
#41513   Well according to Geert, when you finally learn G8TSTFL 05/17/22 06:01:14 PM
#41512   Most micro cap biotechs with cash on hand conix 05/17/22 03:48:30 PM
#41511   True - most of biotech has been hammered drkazmd65 05/17/22 01:20:12 PM
#41510   I believe the whole biotech market is stepping hojake97 05/17/22 12:53:33 PM
#41509   Nice move upward today. Anybody seen any drkazmd65 05/17/22 11:34:42 AM
#41508   Nice Call. Oh wait. You don't rdneum 05/16/22 09:24:10 AM
#41507   What are your thoughts, Sushi? GinGinGin 05/16/22 09:21:23 AM
#41506   PR OUT sushifishman 05/16/22 08:58:41 AM
#41505   :D are you expecting exciting news, Sushi? GinGinGin 05/15/22 09:25:47 AM
#41504   PR Out Tomorrow Chirp Chirp ?? sushifishman 05/15/22 08:58:28 AM
#41503   PR out Monday! Chirp Chirp sushifishman 05/14/22 07:36:37 AM
#41502   Parker Miracle! Wisconsin got the internet just last sushifishman 05/13/22 08:08:48 PM
#41501   I thought you went to the cabin in WI PARker1703 05/13/22 07:55:49 PM
#41500   10Q Out sushifishman 05/13/22 06:03:19 PM
#41499   What I don’t get about this new Data G8TSTFL 05/13/22 10:58:32 AM
#41498   Shabbat Shalom sushifishman 05/13/22 08:59:11 AM
#41497   49.61% daily short volume but PPS up 8.91%! Phoenix2020 05/12/22 10:36:59 PM
#41496   100% agree I've been in both for a while, ggrant3 05/12/22 09:10:15 PM
#41495   I know I’ve said this before, but here G8TSTFL 05/12/22 08:17:53 PM
#41494   Thanks, much appreciated sir. RobotDroid 05/11/22 03:34:20 PM
#41493   Thanks so much for posting this! Dr. Johnny Fever 05/11/22 03:33:47 PM
#41492   Best of luck, Robot. I've enjoyed your Dr. Johnny Fever 05/11/22 03:33:17 PM
#41491   So glad I punted this POS and got RobotDroid 05/11/22 02:10:51 PM
#41490   Hopefully this round (ct,gov results) will pass the exwannabe 05/11/22 01:25:29 PM
#41489   https://www.clinicaltrials.gov/ct2/show/results/NCT01265849?term=multikine&draw= remittekram 05/11/22 10:03:39 AM
#41488   hi sushi I checked out nwbo this week tarius729 05/10/22 07:53:29 PM
#41487   We will see what happens next month at stingman49 05/10/22 04:27:42 PM
#41486   Lock In gains. I did. It’s a sushifishman 05/10/22 12:52:36 PM
#41485   northwest Bio having a similar end to how renaissance1 05/10/22 12:49:20 PM
#41483   Back in the $3s but it was mid sushifishman 05/06/22 07:15:10 PM
#41482   back into the $3s tarius729 05/06/22 04:13:52 PM
#41478   This periodic cycling between $2s and $3s is drkazmd65 05/04/22 02:54:53 PM
#41477   Back Into the $2s sushifishman 05/04/22 02:09:23 PM
#41476   62.56% daily short volume but PPS up 1.56%!! Phoenix2020 05/04/22 02:42:20 AM
#41475   Totally agree. The only long term holding conix 05/03/22 02:13:22 PM
#41474   So I think it’s both long term and hojake97 05/03/22 12:20:57 PM
#41473   No advice offered. Stating the obvious to conix 05/03/22 11:25:32 AM
#41472   Thanks for the advice hojake97 05/03/22 11:20:47 AM
#41471   CVM has been very difficult to trade. conix 05/03/22 09:17:54 AM
#41470   65.93% daily short volume but PPS up 12.24%! Phoenix2020 05/03/22 12:15:00 AM
#41469  Restored Letter to Shareholders by Geert Kersten!! exwannabe 05/02/22 09:37:40 PM
#41468   Thanks for the information Dr. Johnny. drkazmd65 05/02/22 12:16:02 PM
#41467   Dr. Kaz, the letter to shareholders was included Dr. Johnny Fever 05/02/22 11:48:46 AM
PostSubject
Consent Preferences